Overhyped Valuations Will Falter Amid Healthcare Headwinds

Key Takeaways

• Elevated market optimism about Leqembi and pipeline growth may be inflating valuations beyond sustainable long-term profit trends.
  
• High dependence on Leqembi and potential structural headwinds could challenge future revenue and margin expansion.
  
• BioArctic's diversified pipeline, strategic partnerships, and clinical advances position it for sustained growth, recurring revenue, and strong long-term profitability amid expanding market demand.

Catalysts

Develops biological drugs for patients with central nervous system disorders in Sweden.

• The market appears to be assigning high future growth expectations to BioArctic based on accelerating Leqembi (lecanemab) sales driven by an aging global population and the anticipated global rollout of more effective Alzheimer's diagnostics (such as FDA-approved blood-based biomarkers), both of which are likely to boost revenue growth in the next several years.
  
• Strong investor enthusiasm toward rapidly increasing healthcare expenditures and growing government/insurer willingness to fund high-value therapies seem to be supporting elevated valuation multiples, with expectations that BioArctic will retain pricing power and achieve continued margin expansion as Leqembi and pipeline assets scale globally.
  
• Recent record quarterly royalties, new milestone inflows (e.g., European regulatory milestone, Novartis upfront), and exceptionally robust cash balances may be leading investors to believe that future earnings will remain elevated or further accelerate, driving overvaluation relative to normalized, long-term profit trends.
  
• Considerable optimism around the expansion and monetization of the proprietary BrainTransporter platform suggests the market is pricing in a steady pipeline of lucrative new partnerships and long-term upside from advances in precision medicine, which may be front-loading revenue and margin expectations before these platforms are fully validated commercially.
  
• Current valuations may be overstating sustainable growth and profitability by not sufficiently discounting the high concentration risk in Leqembi and the multi-year ramp necessary for other pipeline assets, especially if future growth slows as secular tailwinds-such as global patient pool expansion or payer willingness-face structural or political headwinds impacting future revenue and earnings.

BioArctic Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming BioArctic's revenue will grow by 3.4% annually over the next 3 years.
• Analysts assume that profit margins will shrink from 51.1% today to 15.5% in 3 years time.
• Analysts expect earnings to reach SEK 342.0 million (and earnings per share of SEK 3.88) by about April 2029, down from SEK 1.0 billion today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 92.3x on those 2029 earnings, up from 27.2x today. This future PE is greater than the current PE for the SE Biotechs industry at 17.4x.
• Analysts expect the number of shares outstanding to grow by 0.13% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.31%, as per the Simply Wall St company report.

Risks

• Global demographic trends, including an aging population and rising prevalence of neurodegenerative diseases like Alzheimer's and Parkinson's, are likely to expand BioArctic's addressable market over the coming decades, supporting sustained long-term revenue growth and enhancing the potential for blockbuster drugs.
  
• The company's robust and expanding pipeline, highlighted by proprietary platforms such as BrainTransporter and multiple high-value partnerships (Eisai, Bristol Myers Squibb, Novartis), provides significant revenue diversification, reduces dependency on any single asset, and increases the probability of future milestone and royalty streams that can strengthen profitability and margin expansion.
  
• Strong recent clinical and real-world data on Leqembi (lecanemab), including positive long-term safety and efficacy, approval in nearly 50 countries, and innovations such as subcutaneous administration and blood-based biomarkers, support high adoption rates and facilitate faster expansion into new geographies, bolstering top-line growth and recurring royalties.
  
• The industry trend of large pharmaceutical companies seeking external innovation and active pursuit of collaboration and licensing deals in neuroscience creates a favorable environment for BioArctic to secure additional, potentially lucrative partnerships in the coming years, driving non-dilutive capital inflows (upfronts, milestones) and further strengthening earnings stability.
  
• A strong balance sheet with high cash reserves, ongoing profitability, and improving operational leverage position BioArctic to invest aggressively in R&D, extend its rare disease drug candidates further into clinical development, potentially commercialize assets independently, and even pursue shareholder dividends, all of which support longer-term earnings and investor confidence.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of SEK303.8 for BioArctic based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK367.0, and the most bearish reporting a price target of just SEK240.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK2.2 billion, earnings will come to SEK342.0 million, and it would be trading on a PE ratio of 92.3x, assuming you use a discount rate of 5.3%.
• Given the current share price of SEK314.0, the analyst price target of SEK303.8 is 3.4% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.